Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ·Healthcare·Biotechnology
$2.21
+3.52%
Mkt Cap $6.34M
Analyst Ratings
No recent rating data.
Price Target (1 analysts)
$225.00
Range $225.00 – $225.00
Implied Upside
+10104.1%
Consensus $225.00 vs current $2.21